P2Y nucleotide receptors: promise of therapeutic applications
about
Supportive or detrimental roles of P2Y receptors in brain pathology?--The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studiesP2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cellsPurinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responsesStructure of the human P2Y12 receptor in complex with an antithrombotic drugPermeation of fluorophore-conjugated phalloidin into live hair cells of the inner ear is modulated by P2Y receptors.4-Alkyloxyimino derivatives of uridine-5'-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4, and P2Y6 receptorsSmoking enhances the proinflammatory effects of nucleotides on cytokine release from human lung.Pharmacochemistry of the platelet purinergic receptors.Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modificationsP2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells.Combined blockade of ADP receptors and PI3-kinase p110β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulationPutative roles of purinergic signaling in human immunodeficiency virus-1 infectionStructure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.Selective activation of KCa3.1 and CRAC channels by P2Y2 receptors promotes Ca(2+) signaling, store refilling and migration of rat microglial cellsSelective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation.P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.Differential radial capillary action of ligand assay for high-throughput detection of protein-metabolite interactionsIntercellular Ca(2+) waves: mechanisms and function.Nucleotides Acting at P2Y Receptors: Connecting Structure and Function.G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactionsSustained elevation of extracellular ATP in aqueous humor from humans with primary chronic angle-closure glaucomaVirtual screening leads to the discovery of novel non-nucleotide P2Y₁ receptor antagonists.Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y12 Receptor and Aggregation.Xenin-25 increases cytosolic free calcium levels and acetylcholine release from a subset of myenteric neurons.Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes.Purinergic receptor blockade in the retrotrapezoid nucleus attenuates the respiratory chemoreflexes in awake ratsDo Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?Hypersensitivity to ticagrelor and low response to clopidogrel: a case report.Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future.P2X receptors as drug targets.Independent purinergic mechanisms of central and peripheral chemoreception in the rostral ventrolateral medulla.P2 receptors and platelet function.Analysis of mononucleotides by tandem mass spectrometry: investigation of fragmentation pathways for phosphate- and ribose-modified nucleotide analogues.Challenges to develop novel anti-inflammatory and analgesic drugs.Expression of mediators of purinergic signaling in human liver cell lines.Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.Synthesis of extended uridine phosphonates derived from an allosteric P2Y2 receptor ligand.Facilitation of transmitter release from rat sympathetic neurons via presynaptic P2Y(1) receptors.The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413.
P2860
Q26781042-63C18561-4AE9-454B-9CF4-416CFAD70FF9Q26861200-DEB12034-11C1-4308-AB60-CA48258F500CQ26863398-B53B5C7A-EDF3-4EE3-8029-EE4305BA04C4Q27682517-49A76660-401E-4D6D-B05A-C4A8346C47A7Q30408343-14BE4C67-3E2D-458B-AFD3-64FC1E6A99ABQ33598870-174A7BAD-535D-438D-B7DB-B7DA888177FCQ33825440-5590B99E-FB42-4705-BFB4-B5B8A72B9FF5Q33869922-0FD5017E-BD15-4F64-95A0-0C3412303DE0Q33919264-72D3D3E9-20EF-4A39-913D-054563519166Q34109265-C31FC3F4-54D1-4DE6-A68A-AA2E351FAD5BQ34283297-FE76C58C-BC91-40E9-B239-4DC660923D17Q34305447-F4AB338B-EFBE-4F48-8605-15F788B5C793Q34446486-E7FE7BDC-056B-4D21-B2BE-EB3C80FBB67AQ34676680-5BB36B51-E948-48A3-A661-947915568A26Q34689609-A0DE4D23-1B02-41F7-83D3-F493C573CF9BQ34707637-5C2D4382-A0F7-433D-A555-C6AA60D424E0Q35163180-E628B92A-71E7-4C1D-B19E-A96EC734511FQ35216869-CCE97224-D49E-44C8-BE88-A72A0CDBAF5EQ35831885-C90DF2D4-5240-413D-A83F-6BA0051F6F3FQ35897845-438F7E46-2BA3-400C-B531-6C97E80F797FQ35987700-350D8F2B-A107-426C-9819-EEBB22FB9784Q36030094-6CDE154E-5449-462A-B3BF-8322041867AAQ36168187-99B5D173-6C86-48B9-A803-C4CA51FEEE12Q36266153-9C280FDC-05AD-46BF-9574-F0D02C5A5C14Q36494699-01657A6B-DA40-4B36-BD60-EE2E59E827FFQ36541370-5FBC9C85-9673-4F1F-901B-78BAE3BD1C8DQ36746461-058E8CFD-3254-41E3-845C-21ACD569D212Q37242107-4DDA59C4-FA17-42D1-BD76-D291B5ACC33EQ37618915-FF25D7BE-9C6A-4AA9-A2D2-6CA75A3E571CQ37975129-849308DC-345F-4511-B9C8-94AACDC9D37DQ38068620-416A0424-3DD8-46AA-8911-756CA8CAA113Q38294045-B60BF53B-E347-4AD9-AEA2-FEB71122660AQ38306634-30BF8D68-EE94-4930-8B76-2BF966D64BC3Q38615354-EEE5AA29-279F-43E9-B84A-CE85DB3FA2F0Q38941483-1BE82EAA-87AD-49DC-A380-0BCC98ED4893Q38959199-3B308FD0-225A-40A2-88BB-472F9F8C7740Q38993161-282F0604-98F0-4ECF-ADC0-AA3D3633F78EQ39006256-318830C5-3C42-473E-97B0-05006D48E7FFQ39264632-4C06A8B3-E371-449A-B835-58F559F2D209Q39297464-6AD65B3C-D79E-40D8-A2AF-542FD284DF65
P2860
P2Y nucleotide receptors: promise of therapeutic applications
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
P2Y nucleotide receptors: promise of therapeutic applications
@ast
P2Y nucleotide receptors: promise of therapeutic applications
@en
P2Y nucleotide receptors: promise of therapeutic applications
@nl
type
label
P2Y nucleotide receptors: promise of therapeutic applications
@ast
P2Y nucleotide receptors: promise of therapeutic applications
@en
P2Y nucleotide receptors: promise of therapeutic applications
@nl
prefLabel
P2Y nucleotide receptors: promise of therapeutic applications
@ast
P2Y nucleotide receptors: promise of therapeutic applications
@en
P2Y nucleotide receptors: promise of therapeutic applications
@nl
P2860
P1433
P1476
P2Y nucleotide receptors: promise of therapeutic applications
@en
P2093
Jean-Marie Boeynaems
Kenneth A Jacobson
P2860
P304
P356
10.1016/J.DRUDIS.2010.05.011
P577
2010-06-02T00:00:00Z